Go Deep
CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,076 | 12.2 | 2.29 | 0.02 | 107.17 |
| Oct 2026 | 22,077 | 12.2 | 2.29 | 0.02 | 107.29 |
| Oct 2026 | 22,054 | 12.2 | 2.30 | 0.02 | 107.77 |
| Oct 2026 | 22,184 | 11.9 | 2.24 | 0.02 | 104.85 |
| Oct 2026 | 22,386 | 11.9 | 2.15 | 0.02 | 100.52 |
| Oct 2026 | 22,392 | 11.4 | 2.15 | 0.02 | 100.87 |
| Oct 2026 | 22,460 | 11.3 | 2.12 | 0.02 | 99.63 |
CSPC Pharmaceutical Group Limited Quarterly Results
| Line Item | Mar 2026 | Mar 2025 |
|---|---|---|
| EPS | 0.1 | 0.1 |
CSPC Pharmaceutical Group Limited Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 26,005,980,000.0 | 29,009,254,000.0 | 31,450,109,000.0 | 30,936,904,000.0 | — |
| Net Profit | 3,882,108,000.0 | 4,328,035,000.0 | 5,873,325,000.0 | 6,091,390,000.0 | — |
| EPS | 0.3 | 0.4 | 0.5 | 0.5 | — |
CSPC Pharmaceutical Group Limited Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 46,697,914,000.0 | 44,388,991,000.0 | 46,282,170,000.0 | 41,769,774,000.0 | — |
| Total Liabilities | 12,147,797,000.0 | 10,522,701,000.0 | 11,264,158,000.0 | 10,127,899,000.0 | — |
| Total Equity | 33,178,167,000.0 | 32,264,695,000.0 | 33,203,208,000.0 | 30,197,534,000.0 | — |
Owes vs Owns
CSPC Pharmaceutical Group Limited owed ¥0.30 for every ¥1 it owned in Jun 2026, up from ¥0.24 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.30× | 0.26× | 0.24× | 0.24× | 0.24× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
CSPC Pharmaceutical Group Limited Assets & Liabilities Breakdown (CNY millions)
What it owns — Dec 2025
Cash & short-term investments 19.0%Receivables 10.2%Inventory 6.6%Fixed assets (tangible) 30.1%Intangible assets 6.4%Long-term investments 3.1%Other assets 24.5%
How it's funded — Dec 2025
Short-term debt 0.7%Payables 6.4%Other liabilities 18.6%Shareholders' equity 74.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 8,865.5 | 8,250.3 | 13,092.3 | 13,872.9 |
| Receivables | 4,778.9 | 5,160.7 | 5,869.2 | 3,938.0 |
| Inventory | 3,090.7 | 3,130.0 | 3,138.7 | 2,554.9 |
| Fixed assets (tangible) | 14,045.9 | 13,079.0 | 12,262.0 | 11,773.5 |
| Intangible assets | 3,009.8 | 2,844.4 | 2,433.5 | 2,143.0 |
| Long-term investments | 1,465.6 | 1,526.9 | 1,468.4 | 1,394.8 |
| Other assets | 11,441.6 | 10,397.7 | 8,018.1 | 6,092.8 |
| Liabilities & equity | ||||
| Short-term debt | 328.7 | 392.2 | 450.2 | 153.5 |
| Long-term debt | 180.7 | 56.1 | 0.0 | 28.9 |
| Payables | 2,975.6 | 2,613.0 | 2,841.7 | 2,010.1 |
| Other liabilities | 8,662.8 | 7,461.4 | 7,972.2 | 7,935.4 |
| Shareholders' equity | 34,550.1 | 33,866.3 | 35,018.0 | 31,641.9 |
| Net tangible assets | 30,168.4 | 29,420.3 | 30,769.8 | 28,054.5 |
CSPC Pharmaceutical Group Limited Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 5,831,641,000.0 | 4,534,664,000.0 | 4,178,815,000.0 | 7,627,064,000.0 | — |
| Investing Activities | -3,878,035,000.0 | -3,858,200,000.0 | 865,863,000.0 | -6,795,984,000.0 | — |
| Financing Activities | -2,611,670,000.0 | -5,253,332,000.0 | -2,559,577,000.0 | -1,904,073,000.0 | — |